Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

O Krystufkova, Helmers S Barbasso, P Venalis, V Malmstrom, E Lindroos, J Vencovsky, IE Lundberg

. 2014 ; 16 (5) : 454.

Language English Country Great Britain

Grant support
NT12438 MZ0 CEP Register

INTRODUCTION: Anti-Jo-1 and anti-Ro52 autoantibodies are common in patients with myositis, but the mechanisms behind their production are not known. Survival of autoantibody-producing cells is dependent on B-cell-activating factor of the tumour necrosis factor family (BAFF). BAFF levels are elevated in serum of anti-Jo-1-positive myositis patients and are influenced by type-I interferon (IFN). IFN-producing cells and BAFF mRNA expression are present in myositis muscle. We investigated expression of the receptors for BAFF in muscle tissue in relation to anti-Jo-1 and anti-Ro52/anti-Ro60 autoantibodies and type-I IFN markers. METHODS: Muscle biopsies from 23 patients with myositis selected based on autoantibody profile and 7 healthy controls were investigated for expression of BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Nineteen samples were assessed for plasma (CD138) and B-cell (CD19) markers. The numbers of positive cells per area were compared with the expression of plasmacytoid dendritic cell (pDC) marker blood dendritic cell antigen-2 (BDCA-2) and IFNalpha/beta-inducible myxovirus resistance-1 protein (MX-1). RESULTS: BAFF-R, BCMA and TACI were expressed in five, seven and seven patients, respectively, and more frequently in anti-Jo-1-positive and/or anti-Ro52/anti-Ro60-positive patients compared to controls and to patients without these autoantibodies (P = BAFF-R: 0.007, BCMA: 0.03 and TACI: 0.07). A local association of receptors with B and plasma cells was confirmed by confocal microscopy. The numbers of CD138-positive and BCMA-positive cells were correlated (r = 0.79; P = 0.001). Expression of BDCA-2 correlated with numbers of CD138-positive cells and marginally with BCMA-positive cells (r = 0.54 and 0.42, respectively; P = 0.04 and 0.06, respectively). There was a borderline correlation between the numbers of positively stained TACI cells and MX-1 areas (r = 0.38, P = 0.08). CONCLUSIONS: The expression pattern of receptors for BAFF on B and plasma cells in muscle suggests a local role for BAFF in autoantibody production in muscle tissues of patients with myositis who have anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. BAFF production could be influenced by type-I IFN produced by pDCs. Thus, B-cell-related molecular pathways may participate in the pathogenesis of myositis in this subset of patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17015472
003      
CZ-PrNML
005      
20220411125115.0
007      
ta
008      
170428s2014 xxkd f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13075-014-0454-8 $2 doi
035    __
$a (PubMed)25301447
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kryštůfková, Olga, $d 1955- $7 xx0058260
245    10
$a Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies / $c O Krystufkova, Helmers S Barbasso, P Venalis, V Malmstrom, E Lindroos, J Vencovsky, IE Lundberg
520    9_
$a INTRODUCTION: Anti-Jo-1 and anti-Ro52 autoantibodies are common in patients with myositis, but the mechanisms behind their production are not known. Survival of autoantibody-producing cells is dependent on B-cell-activating factor of the tumour necrosis factor family (BAFF). BAFF levels are elevated in serum of anti-Jo-1-positive myositis patients and are influenced by type-I interferon (IFN). IFN-producing cells and BAFF mRNA expression are present in myositis muscle. We investigated expression of the receptors for BAFF in muscle tissue in relation to anti-Jo-1 and anti-Ro52/anti-Ro60 autoantibodies and type-I IFN markers. METHODS: Muscle biopsies from 23 patients with myositis selected based on autoantibody profile and 7 healthy controls were investigated for expression of BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Nineteen samples were assessed for plasma (CD138) and B-cell (CD19) markers. The numbers of positive cells per area were compared with the expression of plasmacytoid dendritic cell (pDC) marker blood dendritic cell antigen-2 (BDCA-2) and IFNalpha/beta-inducible myxovirus resistance-1 protein (MX-1). RESULTS: BAFF-R, BCMA and TACI were expressed in five, seven and seven patients, respectively, and more frequently in anti-Jo-1-positive and/or anti-Ro52/anti-Ro60-positive patients compared to controls and to patients without these autoantibodies (P = BAFF-R: 0.007, BCMA: 0.03 and TACI: 0.07). A local association of receptors with B and plasma cells was confirmed by confocal microscopy. The numbers of CD138-positive and BCMA-positive cells were correlated (r = 0.79; P = 0.001). Expression of BDCA-2 correlated with numbers of CD138-positive cells and marginally with BCMA-positive cells (r = 0.54 and 0.42, respectively; P = 0.04 and 0.06, respectively). There was a borderline correlation between the numbers of positively stained TACI cells and MX-1 areas (r = 0.38, P = 0.08). CONCLUSIONS: The expression pattern of receptors for BAFF on B and plasma cells in muscle suggests a local role for BAFF in autoantibody production in muscle tissues of patients with myositis who have anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. BAFF production could be influenced by type-I IFN produced by pDCs. Thus, B-cell-related molecular pathways may participate in the pathogenesis of myositis in this subset of patients.
590    __
$a bohemika - dle Pubmed
650    02
$a dospělí $7 D000328
650    02
$a senioři $7 D000368
650    02
$a antinukleární protilátky $x imunologie $7 D000974
650    02
$a antigeny CD19 $x metabolismus $7 D018941
650    12
$a autoprotilátky $x imunologie $7 D001323
650    02
$a faktor aktivující B-buňky $x biosyntéza $7 D053264
650    12
$a receptor faktoru aktivujícího B-buňky $x biosyntéza $7 D053265
650    12
$a maturační antigen B-buněk $x biosyntéza $7 D053301
650    02
$a B-lymfocyty $x metabolismus $x účinky léků $7 D001402
650    02
$a biopsie $7 D001706
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a imunohistochemie $7 D007150
650    02
$a interferon typ I $x farmakologie $7 D007370
650    02
$a mužské pohlaví $7 D008297
650    02
$a konfokální mikroskopie $7 D018613
650    02
$a lidé středního věku $7 D008875
650    12
$a svaly $x metabolismus $x patologie $7 D009132
650    12
$a myozitida $x imunologie $7 D009220
650    12
$a myozitida $x metabolismus $x patologie $7 D009220
650    02
$a ribonukleoproteiny $x imunologie $7 D012261
650    02
$a syndekan-1 $x metabolismus $7 D053668
650    12
$a receptor TACI $x biosyntéza $7 D053303
700    1_
$a Barbasso Helmers S
700    1_
$a Venalis P
700    1_
$a Malmstrom V
700    1_
$a Lindroos E
700    1_
$a Vencovský, Jiří, $d 1953- $7 jo20000080529
700    1_
$a Lundberg IE
773    0_
$t Arthritis Research & Therapy $g Roč. 16, č. 5 (2014), s. 454 $p Arthritis Res Ther $x 1478-6354 $w MED00007534
773    0_
$p Arthritis Res Ther $g 16(5):454, 2014 Oct 10
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20170428105123 $b ABA008
991    __
$a 20220411125113 $b ABA008
999    __
$a ok $b bmc $g 1202720 $s 976259
BAS    __
$a 3
BMC    __
$a 2014 $b 16 $c 5 $d 454 $x MED00007534 $i 1478-6354 $m Arthritis research & therapy
GRA    __
$a NT12438 $p MZ0
LZP    __
$a NLK 2015-B/lp

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...